Piper Sandler Maintains Overweight on Century Therapeutics, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff maintains an Overweight rating on Century Therapeutics (NASDAQ:IPSC) but lowers the price target from $14 to $10.
August 10, 2023 | 7:36 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler has lowered the price target for Century Therapeutics from $14 to $10 while maintaining an Overweight rating.
The lowering of the price target by Piper Sandler indicates a potential decrease in the short-term value of Century Therapeutics' stock. However, the maintained Overweight rating suggests that the stock is still expected to outperform the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100